Genetically engineered natural killer (NK) cells with or without atezolizumab for the treatment of nonsmall cell lung cancer previously treated with PD‐1 and/or PD‐L1 immune checkpoint inhibitors. This evidence concerns the gene PDCD1 and lung cancer.